Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
Rhea-AI Summary
Genelux (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the H.C. Wainwright Global Healthcare Conference from September 9-11, 2024, in New York City. Thomas Zindrick, President, Chairman and CEO, will engage in a fireside chat with Emily Bodnar, Vice President of Equity Research and H.C. Wainwright Biotechnology Analyst, on September 11 at 12:30 p.m. ET.
The presentation will cover Genelux's clinical-stage programs, recent announcements, and upcoming milestones. A webcast of the event will be available, with an archived replay accessible for approximately 90 days on the company's IR page. Genelux will also participate in virtual one-on-one meetings during the conference, offering institutional investors the opportunity to engage directly with management.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, GNLX gained 13.94%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will discuss clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York.
The conversation with Emily Bodnar, Vice President, Equity Research and H.C. Wainwright Biotechnology Analyst, is scheduled to begin at 12:30 p.m. ET on Wednesday, September 11, 2024. A webcast link for the H.C. Wainwright Conference event will be available at https://journey.ct.events/view/d1ba765d-c21b-46c9-8197-e4dd858808f0. An archived replay will be available for approximately 90 days following the event on the company’s IR page.
The Company will also attend virtual one-on-one meetings during the conference. Institutional investors interested in arranging a meeting with Genelux management can register to attend the conference virtually or contact genelux@allelecomms.com.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its’ proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
FAQ
When is Genelux (GNLX) presenting at the H.C. Wainwright Global Healthcare Conference?
Who will be representing Genelux (GNLX) at the H.C. Wainwright conference?
What topics will Genelux (GNLX) discuss at the H.C. Wainwright conference?
How can investors access Genelux 's (GNLX) presentation at the H.C. Wainwright conference?
Will Genelux (GNLX) be available for one-on-one meetings during the H.C. Wainwright conference?
